Treatment with the proteasome inhibitor bortezomib to deplete IgE plasma cells has provided more ambiguous results, in one case reducing circulating IgE and plasma cells but not allergy (102), and in another two studies, reducing IgE and suppressing allergic reactivity (103, 104). Here, IGHE is linked to allergic disease.